Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_assertion type Assertion NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_head.
- NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_assertion description "[This has led to the question of whether EGFR remains a viable target in patients other than those whose tumors contain mutations, and whether the modest activity of cetuximab in colorectal cancer and head and neck cancer represents all that we can expect from inhibition of this pathway in the absence of mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_provenance.
- NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_assertion evidence source_evidence_literature NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_provenance.
- NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_assertion SIO_000772 17189393 NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_provenance.
- NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_assertion wasDerivedFrom befree-2016 NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_provenance.
- NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_assertion wasGeneratedBy ECO_0000203 NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_provenance.